Do I need to exercise on Wegovy?

Yes — resistance training specifically. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Cardio is a bonus; resistance is the non-negotiable.

How fast do results show on GLP-1?

Appetite changes in 1-2 weeks. Visible weight loss usually starts in week 4-6. Significant fat loss accelerates in weeks 12-44 as the dose escalates.

Why am I not losing weight on Wegovy?

Most non-responders fall into 4 buckets: dose hasn't reached maintenance (2.4 mg), titration was interrupted, calorie intake creeps to match satiety, or a hormonal/medical confounder (hypothyroid, PCOS-with-insulin-resistance, sleep apnea). Talk to your prescriber if no measurable loss by week 16 at maintenance dose.

Can I build muscle on a GLP-1?

Yes — with deliberate resistance training and adequate protein. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Lifting 2-3x/week + 1.2-1.6 g/kg ideal-body-weight protein preserves and can grow muscle while losing fat.

Can GLP-1 help with PCOS?

Yes — primarily via weight loss and improved insulin sensitivity. Smaller trials show improved ovulatory cycles and reduced androgen symptoms in women with PCOS. No GLP-1 is FDA-approved for PCOS; use is off-label and weight-driven.

Does GLP-1 work for type 1 diabetes?

No GLP-1 is FDA-approved for type 1 diabetes. Some endocrinologists prescribe semaglutide off-label as an insulin adjunct in T1D with obesity or insulin resistance, but evidence is limited and DKA risk during gastric-emptying changes requires careful monitoring.

Obesity: Symptoms, Risks & GLP-1 Treatment

glpverdict

Subscribe Sign in

Editorial medical reviewFDA & peer-reviewed sourcesUpdated weeklyMedically reviewed content

GLP-1 evidence for chronic weight management

Editorial grades summarizing study quality and convergence. How we grade.

Claim	Grade	Basis
Semaglutide 2.4 mg produces ~14-15% body-weight reduction at 68 weeks Source: NEJM, 2021 (opens in a new tab) STEP-1 (n=1,961) and STEP-3 RCTs with converging results	AStrong evidence	STEP-1 (n=1,961) and STEP-3 RCTs with converging results
Tirzepatide 15 mg produces ~22% body-weight reduction at 72 weeks Source: NEJM, 2022 (opens in a new tab) SURMOUNT-1 (n=2,539); class-leading effect size	AStrong evidence	SURMOUNT-1 (n=2,539); class-leading effect size
Weight regain is the norm if therapy is stopped Source: JAMA, 2023 (opens in a new tab) STEP-1 extension and SURMOUNT-4: ~2/3 of lost weight regained within 12 months	AStrong evidence	STEP-1 extension and SURMOUNT-4: ~2/3 of lost weight regained within 12 months
Semaglutide reduces cardiovascular events in adults with obesity (no diabetes) Source: NEJM, 2023 (opens in a new tab) SELECT (n=17,604), 20% MACE reduction	AStrong evidence	SELECT (n=17,604), 20% MACE reduction
Long-term GLP-1 use causes medullary thyroid cancer in humans Source: accessdata.fda.gov (opens in a new tab) Rodent-only signal; no human cases attributed despite 10+ years post-approval	FNo evidence	Rodent-only signal; no human cases attributed despite 10+ years post-approval

Obesity: Symptoms, Risks & GLP-1 Treatment

Obesity

Overview

Symptoms

Risk factors

Treatment options

GLP-1 evidence for chronic weight management

Related GLP-1 medications

Ozempic

Wegovy

Zepbound

Common questions readers ask

Sources